Roman Kloeckner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/235456/publications.pdf

Version: 2024-02-01

52	1,581	471509	330143
papers	citations	17	37
		h-index	g-index

53	53	53	2054
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week. CardioVascular and Interventional Radiology, 2022, 45, 102-111.	2.0	7
2	Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?. Cancer Imaging, 2022, 22, 5.	2.8	3
3	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports, 2022, 4, 100417.	4.9	6
4	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterology Journal, 2022, 10, 41-53.	3.8	12
5	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Frontiers in Oncology, 2022, 12, 850454.	2.8	7
6	Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. European Radiology, 2022, 32, 6302-6313.	4.5	13
7	Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers, 2022, 14, 2469.	3.7	8
8	Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. Cancers, 2022, 14, 3156.	3.7	0
9	Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 2021, 73, 137-149.	7.3	69
10	High pretreatment static and dynamic alphaâ€fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterology Journal, 2021, 9, 388-397.	3.8	4
11	Evaluation of a Motion Correction Algorithm for C-Arm Computed Tomography Acquired During Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2021, 44, 610-618.	2.0	8
12	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 403-419.	3.7	25
13	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS ONE, 2021, 16, e0249426.	2.5	11
14	Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. Journal of Clinical Medicine, 2021, 10, 2071.	2.4	5
15	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. Frontiers in Oncology, 2021, 11, 696183.	2.8	17
16	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterology Journal, 2021, 9, 590-597.	3.8	9
17	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2732.	2.4	8
18	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. Journal of Hepatology, 2021, 74, 1362-1372.	3.7	74

#	Article	IF	Citations
19	CIRSE Clinical Practice Manual. CardioVascular and Interventional Radiology, 2021, 44, 1323-1353.	2.0	24
20	Reply to: â€œFreiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?â€• Journal of Hepatology, 2021, 75, 489-490.	3.7	3
21	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers, 2021, 13, 3961.	3.7	7
22	Liver Resection for Intrahepatic Cholangiocarcinomaâ€”Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. Journal of Clinical Medicine, 2021, 10, 3559.	2.4	7
23	How COVID-19 kick-started online learning in medical educationâ€”The DigiMed study. PLoS ONE, 2021, 16, e0257394.	2.5	74
24	Online teaching in radiology as a pilot model for modernizing medical education: results of an international study in cooperation with the ESR. Insights Into Imaging, 2021, 12, 141.	3.4	11
25	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers, 2021, 13, 5018.	3.7	16
26	Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. Abdominal Radiology, 2020, 45, 3326-3336.	2.1	4
27	Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clinical Cancer Informatics, 2020, 4, 1027-1038.	2.1	39
28	Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. Journal of Oncology, 2020, 2020, 1-8.	1.3	4
29	Myocardial Mass Corrected CMR Feature Tracking-Based Strain Ratios are Different in Pathologies With Increased Myocardial Mass. Academic Radiology, 2020, , .	2.5	2
30	Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. Journal of Oncology, 2020, 2020, 1-8.	1.3	11
31	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1883-1890.	2.5	9
32	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. Liver International, 2020, 40, 694-703.	3.9	32
33	Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. PLoS ONE, 2020, 15, e0228501.	2.5	5
34	Endovascular simulation training: a tool to increase enthusiasm for interventional radiology among medical students. European Radiology, 2020, 30, 4656-4663.	4.5	11
35	Attitudes Toward Artificial Intelligence Among Radiologists, IT Specialists, and Industry. Academic Radiology, 2020, 28, 834-840.	2.5	39
36	Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter. CardioVascular and Interventional Radiology, 2019, 42, 1441-1448.	2.0	9

#	Article	IF	Citations
37	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. Liver International, 2019, 39, 1307-1314.	3.9	20
38	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treatment Reviews, 2019, 72, 28-36.	7.7	342
39	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. Liver International, 2019, 39, 324-331.	3.9	55
40	Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction: quantitative assessment of flow and perfusion changes using 2D-perfusion angiography following shunt revision. Abdominal Radiology, 2018, 43, 2868-2875.	2.1	12
41	Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. Abdominal Radiology, 2018, 43, 1245-1253.	2.1	12
42	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer, 2018, 18, 489.	2.6	16
43	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1017-1025.	2.0	17
44	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 94-102.	0.5	34
45	Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer, 2016, 16, 758.	2.6	10
46	Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer, 2015, 15, 465.	2.6	105
47	Survival analysis of proposed <scp>BCLC</scp>â€Ɓ subgroups in hepatocellular carcinoma patients. Liver International, 2015, 35, 591-600.	3.9	60
48	Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2015, 38, 352-360.	2.0	95
49	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials, 2014, 15, 311.	1.6	24
50	Fluoroscopy-guided Hepaticoneojejunostomy in Recurrent Anastomotic Stricture after Repeated Surgical Hepaticojejunostomy. Journal of Vascular and Interventional Radiology, 2013, 24, 1750-1752.	0.5	9
51	Radiation exposure in CT-guided interventions. European Journal of Radiology, 2013, 82, 2253-2257.	2.6	67
52	MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2010, 33, 532-540.	2.0	110